Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals

Set Alert for Deals

Richter Swallows Up Estetrol Franchise And More From Stricken Mithra

Gedeon Richter is looking to chart its own path in women’s healthcare and expand its global footprint, after buying up a bundle of businesses and key products and pipeline assets from Belgium’s Mithra.

M & A Deals

Alvotech And Stada Are Back With A Denosumab Biosimilar Deal

With an ustekinumab biosimilar launch in Europe just around the corner, Alvotech and Stada have reconsidered the previously dropped denosumab partnership, while commercial rights to the aflibercept biosimilar go back to Alvotech.

Deals Strategy

Lotus Builds In Southeast Asia With Teva Thailand Acquisition

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

M & A Deals

Viatris Waves Goodbye To API Business

Viatris has marked another milestone in its ongoing transformation by completing the previously-announced divestment of its active pharmaceutical ingredient business to Matrix Pharma Private Limited in India.

Strategy Deals

France Threatens To Block Servier Sale Of Biogaran To Outside Owner

“We have been very clear with Servier that we do not want it to sell Biogaran,” France’s prime minister has indicated, suggesting that a foreign purchaser would face “drastic conditions” attached to any deal.

Deals M & A

Sun-Taro Merger Nearing Completion As Shareholders Vote Yes

Sun Pharma will finally merge with Taro as a single company, after failed attempts to absorb the firm over a decade ago. Also, the firm hints about its upcoming generic portfolio, including GLP-1 products, as well as increasing investment into its specialty business.

Deals M & A

Bio-Thera And Stada Joins Forces On Golimumab, With Up To $160m On The Table

With European biosimilar approvals already in hand for the immunology giants adalimumab and ustekinumab, Stada has allied with Bio-Thera Solutions to bring onboard the commercialization rights for the Chinese firm’s proposed golimumab biosimilar, which currently has a limited pool of chasers.

Biosimilars Deals

Biocon Lines Up Another Liraglutide Deal, This Time In Korea

Biocon has added to its roster of liraglutide partners by striking a fresh deal in Korea with Handok for the chronic weight management treatment.

Deals Generic Drugs

Fosun To Fully Acquire Henlius In Go-Global Push?

Parent Fosun and biosimilars arm Henlius halt share trading on the same day, sparking speculation of a buy-out deal that would assist the Chinese firms' globalization push.

Deals M & A

Gedeon Richter’s Q1 Hit By Weak Ruble But Expects More M&A In Q2

With two M&A deals expected to close in the second quarter, Gedeon Richter counts its wins and losses from a “solid” start to the year.

Deals Strategy

Dr Reddy’s Strikes $67m Deal With Alvotech On Denosumab

Dr Reddy’s has announced a denosumab licensing deal with Alvotech covering the US and Europe, for which the Indian company has broken down the financial details. More broadly, the alliance will also allow Dr Reddy’s to build up its commercial infrastructure for biosimilars in both key markets.

Deals Biosimilars

Gedeon Richter Teases Denosumab Partnering Opportunity In Japan

While investigating the potential of the Japanese market for its denosumab, Gedeon Richter is preparing for several regulatory filings, including its tocilizumab biosimilar.

Biosimilars Deals

'Future Fit' Cipla: Play In Oligonucleotides, Obesity Amid Promoter Stake Action

Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.

Strategy Generic Drugs

MS Pharma Bags Formycon’s Eylea Biosimilar Rights In MENA

With an already established network, Formycon’s aflibercept biosimilar licensee Klinge follows in the same footsteps by picking MS Pharma as its MENA region partner.

Biosimilars Deals

Deals In Bag, Dr Reddy’s Sharpens Top 5 Targeted Home Run

Dr Reddy’s shapes journey to the top 5 league on home turf, backed by a string of deals with big pharma to bridge portfolio gaps and supplement its base business. Can they deliver impactful gains in the competitive Indian market?

Sales & Earnings Strategy

Boehringer Allies With Quallent For Push On Adalimumab

Boehringer Ingelheim has revealed that it will supply its 50mg/ml adalimumab biosimilar to Quallent Pharmaceuticals in the US, under a recently-announced initiative that also involves Teva and Alvotech’s 100mg/ml Humira rival.

Biosimilars Deals
See All
UsernamePublicRestriction

Register